Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / pleiotrophin

pleiotrophin

Basics

Aliases:
This biomarker is also known as:
  • HBNF,
  • heparin affin regulatory protein,
  • HARP,
  • Heparin-binding growth factor 8,
  • OSF-1,
  • heparin-binding growth factor 8,
  • NEGF1,
  • heparin-binding neurite outgrowth-promoting factor 1,
  • heparin-binding growth-associated molecule,
  • Heparin-binding growth-associated molecule,
  • Osteoblast-specific factor 1,
  • HBBM,
  • HBNF-1,
  • pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1),
  • HB-GAM,
  • heparin binding growth factor 8,
  • Heparin-binding neurite outgrowth-promoting factor 1,
  • HBGF8,
  • PTN,
  • osteoblast-specific factor 1,
  • HBGF-8,
  • neurite growth-promoting factor 1,
  • HBNF1,
  • Heparin-binding brain mitogen,
  • heparin-binding brain mitogen,

View in BioMuta

Description…

Pleiotrophin, or PTN, is a secreted growth factor found in osteoblasts and brain tissue. PTN induces neurite outgrowth and is mitogenic for fibroblasts, epithelial, and endothelial cells. It binds anaplastic lymphoma kinase (ALK) which induces MAPK pathway activation, an important step in the anti-apoptotic signaling of PTN and regulation of cell proliferation.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: PTN

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

Pleiotrophin has been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker. Pleiotrophin was also observed up-regulated in lung cancer in this study. Others studies have suggested that pleiotrophin may be an early indicator of lung cancer and might be of use in monitoring the efficacy of therapy.

Performance Comment

PTN, also known as pleiotrophin, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.